Zacks Research Lowers Earnings Estimates for Edesa Biotech

Edesa Biotech, Inc. (NASDAQ:EDSA) – Zacks Research reduced their Q3 2026 earnings estimates for Edesa Biotech in a note issued to investors on Friday, May 22nd. Zacks Research analyst D. Bautz now anticipates that the company will post earnings of ($0.38) per share for the quarter, down from their prior forecast of ($0.23). The consensus estimate for Edesa Biotech’s current full-year earnings is ($0.97) per share. Zacks Research also issued estimates for Edesa Biotech’s Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.13) EPS and FY2028 earnings at ($0.93) EPS.

Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.25).

Several other brokerages have also weighed in on EDSA. Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a report on Friday, March 27th. Wall Street Zen lowered shares of Edesa Biotech from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.00.

Edesa Biotech Trading Down 17.8%

Shares of EDSA stock opened at $7.97 on Thursday. Edesa Biotech has a 1 year low of $0.72 and a 1 year high of $20.32. The firm’s 50 day moving average is $9.19 and its 200-day moving average is $4.49. The firm has a market capitalization of $70.85 million, a price-to-earnings ratio of -5.95 and a beta of 1.26.

Hedge Funds Weigh In On Edesa Biotech

Several large investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new position in Edesa Biotech in the third quarter valued at approximately $36,000. State Street Corp bought a new stake in Edesa Biotech in the fourth quarter valued at approximately $27,000. Diadema Partners LP bought a new stake in Edesa Biotech in the fourth quarter valued at approximately $77,000. Finally, DRW Securities LLC bought a new stake in Edesa Biotech in the fourth quarter valued at approximately $191,000. 5.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edesa Biotech news, CEO Pardeep Nijhawan acquired 30,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $2.22 per share, for a total transaction of $66,600.00. Following the completion of the acquisition, the chief executive officer directly owned 371,702 shares of the company’s stock, valued at approximately $825,178.44. This represents a 8.78% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 51,000 shares of company stock valued at $148,500 in the last quarter. Corporate insiders own 24.40% of the company’s stock.

Edesa Biotech Company Profile

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.